论文信息 - Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. - 字舞流文

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

G. Scagliotti | L. Sequist | F. Shepherd | S. Novello | R. Ramlau | A. Santoro | J. von Pawel | B. Schwartz | F. Barlesi | D. Spigel | A. Favaretto | A. Sandler | W. Akerley | V. Hirsh | D. Shuster | S. Orlov | Qiang Wang | J. Ross | R. V. von Roemeling